title: [Results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan].
abstract: This paper reports results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan. The study included 16312 patients examined in different cities during 2011-2012. It showed that ascoril expectorant (Glenmark) at a standard dose is an effective agent for the treatment of cough in children above 3 years and adults aged up to 78 years with ARVI and acute bronchitis, exacerbation of these conditions or grade I-II chronic obstructire pulmonary disease. Most patients reported good therapeutic effect within 1 day after intake. Ascoril expectorant caused no adverse reactions and was well tolerated by the patients. 91% of the attending physicians describe the drug as highly effective.
authors.forename: T S
authors.initials: TS
authors.lastname: Nurgozhin
authors.forename: A E
authors.initials: AE
authors.lastname: Guliaev
authors.forename: B A
authors.initials: BA
authors.lastname: Ermekbaeva
authors.forename: S K
authors.initials: SK
authors.lastname: Zhaugasheva
authors.forename: G T
authors.initials: GT
authors.lastname: Abuova
authors.forename: É A
authors.initials: ÉA
authors.lastname: An
mesh_terms: D000293:Adolescent; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects; D001964:Bromhexine / Q000008:administration & dosage / Q000009:adverse effects; D002675:Child, Preschool; D003371:Cough / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004338:Drug Combinations; D016903:Drug Monitoring; D005100:Expectorants / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006140:Guaifenesin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007623:Kazakhstan; D008297:Male; D010045:Outpatients; D062072:Patient Acuity; D012141:Respiratory Tract Infections / Q000145:classification / Q000150:complications* / Q000503:physiopathology; D016896:Treatment Outcome; D014610:Uzbekistan
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D004338:Drug Combinations; D005100:Expectorants; D006140:Guaifenesin; D001964:Bromhexine; D000420:Albuterol